Newer insulins in search of a niche

Annals of Internal Medicine

Volumn 149, Issue 8, 2008, Pages 586-588

  Majumdar, Sachin ^a   Barrett, Eugene ^a  

^a UNIVERSITY OF VIRGINIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HUMAN INSULIN; INSULIN; INSULIN ASPART; INSULIN DERIVATIVE; INSULIN GLARGINE; INSULIN GLULISINE; INSULIN LISPRO; METFORMIN; NEUTRAL PROTAMINE LISPRO INSULIN; SULFONYLUREA; UNCLASSIFIED DRUG; ANTIDIABETIC AGENT; DRUG DERIVATIVE;

DIABETES MELLITUS; DRUG EFFICACY; DRUG SAFETY; EDITORIAL; GLYCEMIC CONTROL; HUMAN; INSULIN TREATMENT; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; DRUG FORMULATION; NOTE;

DIABETES MELLITUS, TYPE 2; DRUG COMPOUNDING; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN;

EID: 54549117072     PISSN: 00034819     EISSN: None     Source Type: Journal    
DOI: 10.7326/0003-4819-149-8-200810210-00011     Document Type: Editorial

References (18)

1. National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health. National Diabetes Statistics, 2007. Accessed at http: //diabetes.niddk.nih.gov/dm/pubs/statistics/#pre-diabetes on 16 September 2008.
2. American Diabetes Association. Economic costs of diabetes in the U.S. In 2007. Diabetes Care. 2008;31:596-615. [PMID: 18308683]
3. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med. 1993; 329:977-86. [PMID: 8366922]
4. Nathan DM, Cleary PA, Backlund JY, Genuth SM, Lachin JM, Orchard TJ, et al. Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Study Research Group. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med. 2005;353:2643-53. [PMID: 16371630]
5. Hypoglycemia in the Diabetes Control and Complications Trial. The Diabetes Control and Complications Trial Research Group. Diabetes. 1997;46:271-86. [PMID: 9000705]
6. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 1998;352:837-53. [PMID: 9742976]
7. Wright AD, Cull CA, Macleod KM, Holman RR. The UKPDS Group. Hypoglycemia in Type 2 diabetic patients randomized to and maintained on monotherapy with diet, sulfonylurea, metformin, or insulin for 6 years from diagnosis: UKPDS73. J Diabetes Complications. 2006;20:395-401. [PMID: 17070446]
8. Becker RH, Frick AD. Clinical pharmacokinetics and pharmacodynamics of insulin glulisine. Clin Pharmacokinet. 2008;47:7-20. [PMID: 18076215]
9. Chapman TM, Noble S, Goa KL. Insulin aspart: a review of its use in the management of type 1 and 2 diabetes mellitus. Drugs. 2002;62:1945-81. [PMID: 12215068]
10. Holleman F, Hoekstra JB. Insulin lispro. N Engl J Med. 1997;337:176-83. [PMID: 9219705]
11. Oiknine R, Bernbaum M, Mooradian AD. A critical appraisal of the role of insulin analogues in the management of diabetes mellitus. Drugs. 2005;65:325-40. [PMID: 15669878]
12. Riddle MC, Rosenstock J, Gerich J. Insulin Glargine 4002 Study Investigators. The treat-to-target trial: randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients. Diabetes Care. 2003;26:3080-6. [PMID: 14578243]
13. Vague P, Selam JL, Skeie S, De Leeuw I, Elte JW, Haahr H, et al. Insulin detemir is associated with more predictable glycemic control and reduced risk of hypoglycemia than NPH insulin in patients with type 1 diabetes on a basal-bolus regimen with premeal insulin aspart. Diabetes Care. 2003;26:590-6. [PMID: 12610006]
14. Heise T, Nosek L, Rønn BB, Endahl L, Heinemann L, Kapitza C, et al. Lower within-subject variability of insulin detemir in comparison to NPH insulin and insulin glargine in people with type 1 diabetes. Diabetes. 2004;53:1614-20. [PMID: 15161770]
15. Holleman F, Gale EA. Nice insulins, pity about the evidence [Editorial]. Diabetologia. 2007;50:1783-90. [PMID: 17634918]
16. Esposito K, Ciotola M, Maiorino MI, Gualdiero R, Schisano B, Ceriello A, et al. Addition of neutral protamine lispro insulin or insulin glargine to oral type 2 diabetes regimens for patients with suboptimal glycemic control. A randomized trial. Ann Intern Med. 2008;149:531-9.
17. Roach P, Woodworth JR. Clinical pharmacokinetics and pharmacodynamics of insulin lispro mixtures. Clin Pharmacokinet. 2002;41:1043-57. [PMID: 12403642]
18. Qayyum R, Bolen S, Maruthur N, Feldman L, Wilson LM, Marinopoulos SS, et al. Systematic review: comparative effectiveness and safety of premixed insulin analogues in type 2 diabetes. Ann Intern Med. 2008;149:549-59.